Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

18

Revenue 2017

Takeda

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Takeda's 2013 sales performance.

Takeda

Deal Watch October 2018

Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... and liver disorders. Licence. $690m. Molecular Templates/. Takeda. CD38‐ targeted engineered toxin bodies (ETBs) for the.

FDA clears first-line use for J&J’s myeloma drug Darzalex

FDA clears first-line use for J&J’s myeloma drug Darzalex The company’s Janssen unit says Darzalex (daratumumab) has been given the nod for use alongside Takeda’s Velcade (bortezomib), melphalan and prednisone (VMP) for newly-diagnosed myeloma patients who are

Pfizer claims rapid FDA nod for Lorbrena

Pfizer claims rapid FDA nod for Lorbrena Xalkori has, however, seen sales dwindle due to competition from newer drugs such as Novartis’ Zykadia and Takeda’s Alunbrig.

Shire’s angioedema drug Takhzyro recommended in Europe

Shire’s angioedema drug Takhzyro recommended in Europe Approved in the US in August, the drug is important for Shire, which is in the midst of a $62bn acquisition by Takeda. ... The news will help bolster Takeda CEO Christophe Weber’s argument that the deal makes sense.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics